We found that USP22 deficiency only enhances the vulnerability of melanoma to ferroptosis inducer RSL3 and has no sensitizing effect on other antimelanoma drugs or cell death inducers (Figures 7A and S7A), suggesting that USP22 has a specific sensitization effect on melanoma ferroptosis. The gene discussed is USP22; the disease is melanoma.